PMA device
Amvisc & Amvisc Plus Ovd
Bausch & Lomb, Inc. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Jul 19, 2002, newest Feb 17, 2017Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
544
Naming "Amvisc Amvisc Plus"
MAUDE reports
0
Brand "Amvisc Amvisc Plus", since 2015
PubMed studies
0
Mentioning "Amvisc Amvisc Plus"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Amvisc & Amvisc Plus Ovd
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- AMVISC & AMVISC PLUS OVDPMA supplement
P810025-S038 · Decided Feb 17, 2017 · 86 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
- AMVISC & AMVISC PLUS (OPHTHALMIC VISCOSURGICAL DEVICES)PMA supplement
P810025-S029 · Decided Jan 17, 2012 · 474 days after receipt · Normal 180 Day Track No User Fee
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
- AMVISC & AMVISC PLUSPMA supplement
P810025-S028 · Decided May 15, 2012 · 694 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Amvisc Amvisc Plus", any status and sponsor, newest update first.
- Hyaluronic Acid Barrier in ParotidectomyNot yet recruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07941011 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2029
Device: Axoguard HA+ Nerve Protector · For: Parotidectomy, Patient-reported Outcomes; Parotid Cancer; Parotid Gland Tumor and 2 more
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
Fatih Sultan Mehmet Training and Research HospitalAcademic, hospital or other
NCT07487038 · 133 participants · Start Jan 1, 2023 · Primary completion Dec 31, 2025
Device: Intra-articular hyaluronic acid injection · For: Knee Osteoarthristis; Hyaluronic Acid
Sites: Ataşehir, Turkey (Türkiye)
541 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Amvisc Amvisc Plus", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LZP
1,607 reports: 550 malfunction, 1,056 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0110-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
Z-0111-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
Z-0112-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Amvisc Amvisc Plus"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)Johnson & Johnson Surgical Vision, Inc. · PMA 2024
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Ocucoat (2% Hydroxpropylmethylcellulose Solution)Bausch & Lomb, Inc. · PMA 2012
- Biolon (1% Sodium Hyaluronate for Ophthalmic Surgery)Altacor , Ltd. · PMA 2005
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.